VYVGART Argenx Australia Pty Ltd
Product name
VYVGART
Sponsor
Accepted date
Apr-2024
Active ingredients
efgartigimod alfa
Proposed indication
As add-on to standard therapy for the treatment of generalized myasthenia gravis (gMG).
Application type
A (new medicine)
Publication date
Apr-2024